BRIEF-BioXcel Therapeutics To Announce Topline Results From Serenity At-Home Pivotal Phase 3 Safety Trial For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia On August 27, 2025

Reuters
Aug 27
BRIEF-BioXcel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> To Announce Topline Results From Serenity At-Home Pivotal Phase 3 Safety Trial For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia On August 27, 2025

Aug 26 (Reuters) - BioXcel Therapeutics Inc BTAI.O:

  • BIOXCEL THERAPEUTICS TO ANNOUNCE TOPLINE RESULTS FROM SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA ON AUGUST 27, 2025

Source text: ID:nGNX1f34z6

Further company coverage: BTAI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10